Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica.

Geneial, a company advancing private, community-led genetic medicine, has been awarded a one-year pilot project through National Heart, Lung.

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the launch of ProPhet, a new startup leveraging artificial intelligence to identify active small molecules for drug discovery.

Global pharma major Lupin Limited (Lupin) today announced its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential (GWP). This initiative aims to provide patients with pressurised

AbbVie and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology

The life science group Sartorius has published its second edition High-Throughput Screening (HTS) by Cytometry handbook. This handbook is designed to empower both new and seasoned flow cytometry users who are curious about the unique capabilities of HTS cytometry. Those using traditional systems will learn

The third-generation oral breast cancer new drug, AND019, independently developed by Kind Pharmaceuticals LLC has received IND approval by the US FDA. This is a second innovative drug approved for clinical development

Merck known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in gynecologic cancers.

Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc.,

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer were updated to recommend ribociclib (Kisqali®) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone